News FDA warns of genital gangrene risk with diabetes drug class The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including one fatality, after using SGLT2 class drugs for type 2 diabetes.
Views & Analysis SGLT2 inhibitors: an emerging option for cardiologists? With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.
UK & Europe AZ’s diabetes combination Qtern approved in Europe The European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2 diabetes.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
